

邀请函：2025 诺和诺德 INNOVO®公开招募创新靶点/机理项目

正在为慢性代谢疾病另辟蹊径？诺和诺德助你一臂之力！

听说你手握创新想法？正在为慢性代谢疾病疗法另辟蹊径？需要更多支持来验证科学假设？

是否有意让我们助你一臂之力？我们提供资源，协助你验证概念假设。没有任何附加条件。我们的期望是多方联手，推动科研创想尽快转化为惠及患者的创新疗法。

我们提供怎样的帮助？

- 研究资金：35 万人民币，以开展关键性实验，验证假设。
- 没有任何附加条件：你享有所有相关知识产权及发表成果的自由。
- 专家指导：来自诺和诺德全球药物发现及开发领域的专家为你提供反馈。
- 资源：诺和诺德共享的化合物试剂、体外实验平台。
- 潜在合作机会：由此开始你的药物发现之旅，有潜力的研究成果有可能会开启你与诺和诺德更深入/长期的合作。

我们招募怎样的研究者及项目？

关于**研究者**，我们希望……

- 有热情探索创新性新靶点、新机理在药物开发方向的转化潜力
- 有明确的实验计划（决定性实验），获取关键性数据，验证假设

关于**项目**，我们希望寻找有潜力提供新的药物靶点、致病机理的研究项目。我们着意关注的研究方向包括：

糖尿病

- 降低血糖之外的其他疗效，例如降低并发症风险
- 胰岛素抵抗的逆转
- 防止疾病进展，例如保护 beta 细胞健康（1 型糖尿病/2 型糖尿病）

肥胖症

- 增强能量消耗
- 调节进食（例如享乐性和奖赏性相关的信号通路）
- 调控对抗调节机理（例如代谢平衡点）

心血管疾病

- 动脉粥样硬化性心血管疾病、射血分数保留的心力衰竭、心肌病
- 在降脂和降炎症的基础上进一步降低风险的作用机理
- 心衰的精准医疗
- 改变疾病进程的疗法（例如基因治疗）

肾病

- 慢性肾病/糖尿病肾病、多囊性肾病、肾小球肾炎
- 纤维溶解/抑制纤维生成
- 保持血管和肾小球完整性

肝病（非酒精性脂肪性肝炎）

- 纤维溶解/抑制纤维生成
- 抑制慢性炎症
- 肝再生
- 非侵入性诊断生物标志物

罕见病

- 罕见非恶性血液疾病
- 罕见代谢性疾病

怎样申请？

- 全年接受申请
- 鼓励**尽快申请**。我们会随即启动评估，快速提供反馈
- 无须海量申请资料，**1-2 页英文内容**描述项目及验证假设的实验计划即可
- 评选标准与申请示例请参看文末。

怎样评估？

- 创新性
- 作为治疗方案的潜力
- 明确的科学假设和关键性验证实验设计（完成可行性）

条款和条件

[validation-nn-terms-conditions.pdf](#)，建议在提交申请前完整阅读此处内容。

有更多问题？

欢迎联系：张睿 博士 +86 18511650956 / innovo@novonordisk.com

评选标准

Proposal evaluation criteria

- Scientific novelty and impact: new targets, mechanisms of action, pathway analyses, etc. (The proposal must contain a novel and clearly defined scientific hypothesis substantiated by the preliminary data and is feasible to explore in a short-term collaboration).
- Clear hypothesis and experimental plan: a concise description of the idea and research plan (The proposed study design can properly address the scientific hypothesis, with a focus on 'killer experiments').
- "Killer experiments": proof of principle experiments that will confirm or refute your hypothesis as valid for continued experimentation (The 'killer experiments' should be feasible to conduct within 6-9 months, not comprehensive and open-ended characterization efforts).

申请示例

Proposal example

1. WHAT IS INNOVATIVE/NOVEL ABOUT YOUR PROPOSAL?

(Please specify the disease area such as T2D, obesity Or CVD, and describe the proposed MOA of your target, and how it can advance our current understanding and treatment of the disease.)

Example: The discovery that inhibiting the target by global attenuation of expression leads to loss of body mass and adiposity is highly novel. Hence, our proposal that inhibiting this impacts organismal nutrient sensing and fuel choice, inducing a metabolic shift that promotes lipid catabolism is highly conceptually innovative. We support this proposal with preliminary data showing a rapid, dramatic shift in the respiratory exchange ratio, reduced body mass and adiposity, and alterations in the level of circulating hormones, despite no discernable effect on food intake, body temperature, or activity level.

2. WHAT IS THE MEDICAL OR TECHNICAL PROBLEM TO BE SOLVED AND WHAT IS THE UNMET NEED THAT DRIVES THE PROJECT?

Example: Identifying new or complementary strategies to mitigate obesity remains a major healthcare priority. An area of particular interest relates to the modulation of central carbon metabolism and lipogenesis as a means to control adiposity.

3. WHICH 'KILLER EXPERIMENTS'/DATA ARE CRITICAL TO CONFIRM/REFUTE YOUR HYPOTHESIS?

(Please describe the key conclusive experiment that can serve as the stop/go signal, which should be able to finish within 6-9 months involving no more than

three in vitro or in vivo experiments. Biological proof of concept in the human system would be a plus.)

Example: (1) Investigate the secretion pattern of xxxxx using the primary mouse or human xxxxx cells. (2) Evaluate the influence of xxxxx on glucose uptake in both mouse and human xxxxx cells by examining xxxxx. (3) Testing if XXX has an impact on XXX by analyzing levels of XXX in both mouse and human cells.

4. WHAT COMPETENCIES AND RESOURCES DOES YOUR TEAM HAVE TO COMPLETE THE STUDY?

(Please describe the research experience and facility you need for the proposed project, and potential collaborators you can access to for certain technology or assays required in this study.)

Example: We are a major medical center with full access to resources and core facilities necessary to carry out the goals of this project. We have state of the art animal facilities and mouse models. Study PI has extensive expertise in the metabolic pathway being targeted and has established a collaborative network at XXX and beyond for analysis of phenotypes related to obesity and diabetes.

*[点击此处提交申请](#)。

*本招募项目为诺和诺德全球合作者招募举措的一部分，提交申请通过全球平台进行。